Gregory Renza
Stock Analyst at RBC Capital
(2.06)
# 2,806
Out of 4,873 analysts
206
Total ratings
32.63%
Success rate
-4.21%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Outperform | $31 → $35 | $46.84 | -25.28% | 3 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Outperform | $26 | $22.42 | +15.99% | 16 | May 19, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $8 | $2.85 | +180.70% | 12 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Sector Perform | $5 | $2.06 | +142.72% | 11 | May 14, 2025 | |
| EXEL Exelixis | Reiterates: Outperform | $40 | $45.72 | -12.51% | 10 | May 14, 2025 | |
| ONC BeOne Medicines | Maintains: Outperform | $312 → $311 | $266.80 | +16.57% | 2 | May 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $182 → $172 | $108.11 | +59.10% | 14 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $35 → $32 | $7.34 | +335.97% | 3 | May 2, 2025 | |
| AMGN Amgen | Maintains: Outperform | $324 → $320 | $277.49 | +15.32% | 17 | May 2, 2025 | |
| CGON CG Oncology | Maintains: Outperform | $66 → $68 | $25.79 | +163.67% | 3 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $15 | $3.82 | +292.67% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $15.72 | -23.66% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $4.56 | +207.02% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $27 | $11.97 | +125.56% | 11 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $21.78 | +180.14% | 12 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $24.62 | -26.89% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $5.57 | +761.76% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 → $10 | $2.05 | +387.80% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $7 → $10 | $3.99 | +150.63% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $14.66 | +220.71% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $33.42 | +70.56% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $7.19 | -44.37% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $11 → $2 | $0.60 | +233.00% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $34 | $8.27 | +311.12% | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $5.31 | +201.32% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $4.92 | +3,558.54% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $1.63 | +4,807.98% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.98 | +2,949.71% | 3 | Jun 2, 2020 |
Cidara Therapeutics
May 23, 2025
Maintains: Outperform
Price Target: $31 → $35
Current: $46.84
Upside: -25.28%
ACADIA Pharmaceuticals
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $22.42
Upside: +15.99%
ADC Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $2.85
Upside: +180.70%
Inovio Pharmaceuticals
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $2.06
Upside: +142.72%
Exelixis
May 14, 2025
Reiterates: Outperform
Price Target: $40
Current: $45.72
Upside: -12.51%
BeOne Medicines
May 8, 2025
Maintains: Outperform
Price Target: $312 → $311
Current: $266.80
Upside: +16.57%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $108.11
Upside: +59.10%
Bicycle Therapeutics
May 2, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $7.34
Upside: +335.97%
Amgen
May 2, 2025
Maintains: Outperform
Price Target: $324 → $320
Current: $277.49
Upside: +15.32%
CG Oncology
Apr 29, 2025
Maintains: Outperform
Price Target: $66 → $68
Current: $25.79
Upside: +163.67%
Mar 27, 2025
Maintains: Outperform
Price Target: $16 → $15
Current: $3.82
Upside: +292.67%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $15.72
Upside: -23.66%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $4.56
Upside: +207.02%
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $11.97
Upside: +125.56%
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $21.78
Upside: +180.14%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $24.62
Upside: -26.89%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $5.57
Upside: +761.76%
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $2.05
Upside: +387.80%
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $3.99
Upside: +150.63%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $14.66
Upside: +220.71%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $33.42
Upside: +70.56%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $7.19
Upside: -44.37%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $11 → $2
Current: $0.60
Upside: +233.00%
Sep 26, 2024
Maintains: Outperform
Price Target: $31 → $34
Current: $8.27
Upside: +311.12%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $5.31
Upside: +201.32%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $4.92
Upside: +3,558.54%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $1.63
Upside: +4,807.98%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.98
Upside: +2,949.71%